Hexa Research Inc.

Industry Research,Custom Research & Consulting

Asia Pacific Insulin Market Size, Market Share, Application

Analysis, Regional Outlook, Growth, Trends, Competitive
Scenario And Forecasts, 2012 To 2020

Industry Insights
Increasing prevalence of type I and type II diabetes is expected to drive the entire insulin market over
the forecast period. Basically, insulin is a peptide hormone secreted with the help of beta cells by
pancreas. The main function of insulin is to enable the absorption of glucose from the blood in the body
which provides energy to the body and stabilize the level of blood glucose.
Continuous changing food habit of people coupled with changing life style is anticipated to increase the
rate of obsessed population which is a factor triggering the market for diabetes. Furthermore, other
factors which support the growth of this market are increasing demand of insulin analogs are rapid
increase in geriatric population and growing demand for minimal invasive and noninvasive treatment for
diabetes.
Browse Detail Report With TOC @ http://www.hexaresearch.com/research-report/asia-pacificinsulin-industry

Hexa Research Inc.

Industry Research,Custom Research & Consulting
Increasing availability of safety pen needles and syringe in the market is pushing the growth of this
market owing to the effective delivery of insulin. Both the public and private firms are taking active
participation for eradication and control of diabetes by investing huge amount of fund for research and
development. Increasing rate of hypertension and destruction of beta cells are the prime reason for
occurrence of diabetes in ones body.
The developing nations consists significant large potential market for insulin which is needed to be
served in order to maximize the revenue and total market share. Continuous introduction of minimal
invasive diagnostic procedures has created a wide gap between the demand and supply of insulin for
the control of glucose level in blood.
Strong government support such as providing grants and subsidies to insulin producing pharmacies is
likely to trigger the demand for insulin in coming five years. High production complexities and cost of
production are the restrains of insulin market. Rising target base population and increasing level of
awareness among people about treatment of diabetes is expected to drive the market in future.
Request A Sample copy of This Report @ http://www.hexaresearch.com/sample/133
Product Insight
By product, the global insulin market is classified into rapid acting, intermediate acting, short acting,
long acting and pre-mixed insulin. Among these, long acting insulin and immediate acting insulin
together contributed almost half of the entire insulin market share by revenue, in 2013. Due to quick
result of balancing blood sugar level, the immediate acting insulin is anticipated to witness lucrative
growth over the forecast period. Apart from this, it has also widely accepted by medical practitioners of
hospitals and clinics.
Long acting insulin segment is also expected to grow with significant rate owing to stabilize the level of
blood glucose for few weeks. This is a very effective way to control diabetes and has long lasting effect.
However, the dose of insulin is prescribed by doctors which depends on various individuals such as
consumption of alcohol, age of individual, consumption of junk foods, personal insulin production rate
and blood glucose level.
Regional Insight
Asia Pacific region comprises of India, China, Australia, South Korea, Brazil and Others developing
nations. This region is anticipated to witness the highest growth rate over the forecast period owing to

Hexa Research Inc.

Industry Research,Custom Research & Consulting
continuous increase in population leading to raise the overall targeted market, rapidly increasing
geriatric population base and rising awareness about diabetes & its treatment. Continuous improvement
in healthcare infrastructure coupled with availability of sophisticated technology is likely to push the
growth of this market in next decade.
Competitors Insight
The market is oligopolistic in nature and there is strong barrier in entry into this industry. Some of the
major market players of the global insulin market are Sanofi, Eli Lilly and Company, Novo Nordisk A/S,
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and Biocon. The prices of these companies product are
entirely dependent in each other.
Table of Contents
Chapter 1. Executive Summary
1.1. Asia Pacific Insulin - Industry Summary and Critical Success Factors (CSFs)
Chapter 2. Asia Pacific Insulin Industry Outlook
2.1. Market Segmentation
2.2. Market Size and Growth Prospects
2.3. Asia Pacific Insulin Market Dynamics
2.4. Key Opportunities Prioritized
2.5. Industry Analysis - Porter's
2.6. Asia Pacific Insulin - Company Market Share Analysis
2.7. Asia Pacific Insulin Market PESTEL Analysis, 2012
2.8. Asia Pacific Insulin Pipeline Overview
Browse All Pharmaceuticals Industry Research Related Reports @
http://www.hexaresearch.com/research-category/pharmaceuticals-industry/
Chapter 3. Asia Pacific Insulin Product Outlook, Volume (number of units) and Value (USD Million)
Estimates and Forecasts, 2012 - 2020
3.1. Rapid Acting Analog
3.2. Short Acting Insulin
3.3. Intermediate Acting Insulin
3.4. Long Acting Analog

Hexa Research Inc.

Industry Research,Custom Research & Consulting
3.5. Pre-Mixed
Chapter 4. Asia Pacific Insulin Segment (on the basis of source) Outlook, Volume (number of units) and
Value (USD Million) Estimates and Forecasts, 2012 - 2020
4.1. Insulin Analogs
4.2. Human Recombinant Insulin
Chapter 5. Asia Pacific Insulin Application Outlook (USD Million) Estimates and Forecasts, 2012 - 2020
5.1. Type I and Other Diabetes
5.2. Type II Diabetes
Chapter 6. Insulin Regional Outlook, Volume (number of units) and Value (USD Million) Estimates and
Forecasts, 2012 - 2020
6.1. India
6.2. China
6.3. Australia
6.4. New Zealand
6.5. South Korea
6.6. Taiwan
6.7. Philippines
6.8. Vietnam
6.9. Indonesia
6.10. Japan
6.11. Malaysia
6.12. Thailand
6.13. Rest of Asia Pacific
Chapter 7 Competitive Landscape
7.1 Novo Nordisk
7.2 Sanofi
7.3 Eli Lilly
7.4 Bristol-Myers Squibb
7.5 Novartis
7.6 Takeda Pharmaceuticals
7.7 Boehringer Ingelheim
7.8 Biocon

Hexa Research Inc.

Industry Research,Custom Research & Consulting
7.9 Dongbao Enterprise Group Co., Ltd.
7.10 Merck KGaA
7.11 Oramed Pharmaceuticals Inc.
7.12 Halozyme Therapeutics
7.13 Wanbang Biopharma
7.14 Xinbai Pharmaceutical
7.15 Gan & Lee Pharmaceutical
Browse Full Report @ http://www.hexaresearch.com/research-report/asia-pacific-insulin-industry
About Us:
Hexa Research is a market research and consulting organization, offering industry reports, custom
research and consulting services to a host of key industries across the globe. We offer comprehensive
business intelligence in the form of industry reports which help our clients obtain clarity about their
business environment and enable them to undertake strategic growth initiatives.
Contact Information:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Email: sales@hexaresearch.com
Website - http://www.hexaresearch.com/
Visit our Blogs: http://2015hexaresearchpapers.blogspot.in/